177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
Status:
Recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
Children and adolescents diagnosed with medullablastoma and with recurrent or refractory to
frontline therapy will be treated with 177Lu-DTPA-omburtamab, which is a radioactive
labelling of a murine monoclonal antibody targeting B7-H3.